A Catalytic DNA Activated by a Specific Strain of Bacterial Pathogen

Wu, Zai‐Sheng; Chang, Dingran; Zhang, Wenqing; Tram, Kha; Lee, Christine; Kim, Peter; Salena, Bruno J.; Li, Yingfu

doi:10.1002/ange.201510125

Cited by 38 publications

(32 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since each urease can turnover ~10 14 times, another layer of signal amplification was achieved, allowing a detection limit of ~10 3 E.coli cells (without cell culturing) with high selectivity. More recently, the same group further moved forward by reporting a novel DNAzyme that can recognize specific strain of bacterial with exquisite selectivity 108. They also implemented this selection strategy to isolate DNAzyme for cancer cell detection 109.…”

Section: Bacterial and Cancer Cell Sensingmentioning

confidence: 99%

Theranostic DNAzymes

Zhou¹,

Ding²,

Liu³

2017

Theranostics

204

145

View full text Add to dashboard Cite

DNAzymes are catalytically active DNA molecules that are obtained via in vitro selection. RNA-cleaving DNAzymes have attracted significant attention for both therapeutic and diagnostic applications due to their excellent programmability, stability, and activity. They can be designed to cleave a specific mRNA to down-regulate gene expression. At the same time, DNAzymes can sense a broad range of analytes. By combining these two functions, theranostic DNAzymes are obtained. This review summarizes the progress of DNAzyme for theranostic applications. First, in vitro selection of DNAzymes is briefly introduced, and some representative DNAzymes related to biological applications are summarized. Then, the applications of DNAzyme for RNA cleaving are reviewed. DNAzymes have been used to cleave RNA for treating various diseases, such as viral infection, cancer, inflammation and atherosclerosis. Several formulations have entered clinical trials. Next, the use of DNAzymes for detecting metal ions, small molecules and nucleic acids related to disease diagnosis is summarized. Finally, the theranostic applications of DNAzyme are reviewed. The challenges to be addressed include poor DNAzyme activity under biological conditions, mRNA accessibility, delivery, and quantification of gene expression. Possible solutions to overcome these challenges are discussed, and future directions of the field are speculated.

show abstract

Section: Bacterial and Cancer Cell Sensingmentioning

confidence: 99%

Theranostic DNAzymes

Zhou¹,

Ding²,

Liu³

2017

Theranostics

204

145

View full text Add to dashboard Cite

show abstract

“…Isolated with an in vitro process called Systematic Evolution of Ligand by EXponential enrichment, or SELEX (Ellington and Szostak, 1990, Tuerk and Gold, 1990, Beaudry and Joyce, 1992, Ellington and Szostak, 1992, Breaker et al, 1994), DNA/RNA aptamers and DNAzymes/ribozymes can be isolated to bind to a wide range of targets with high affinity and specificity, including metal ions, small molecules, protein and even virus or whole cell, making them one of the most versatile recognition elements (Lu and Liu, 2006, Navani and Li, 2006, Shangguan et al, 2006, Mok and Li, 2008, Li and Lu, 2009, Liu et al, 2009, Wu et al, 2010, Sai Lau and Li, 2011, Zhang et al, 2011, Ali et al, 2012, Torabi and Lu, 2014, Xiang and Lu, 2014, Shen et al, 2015). In addition to target-binding capability, DNAzymes can catalyze chemical reactions, the most common being hydrolysis of a phosphodiester bond (Breaker et al, 1994, Carmi et al, 1996, Santoro and Joyce, 1997, Carmi et al, 1998, Santoro and Joyce, 1998, Li et al, 2000, Carmi and Breaker, 2001, Brown et al, 2003, Liu et al, 2007, Brown et al, 2009, Torabi et al, 2015).…”

Section: Design Of the Bgm-based Biosensors For Ivds Of Non-glucosmentioning

confidence: 99%

Transforming the blood glucose meter into a general healthcare meter for in vitro diagnostics in mobile health

Lan

Zhang

2016

Biotechnology Advances

View full text Add to dashboard Cite

Recent advances in mobile network and smartphones have provided an enormous opportunity for transforming in vitro diagnostics (IVD) from central labs to home or other points of care (POC). A major challenge to achieving the goal is a long time and high costs associated with developing POC IVD devices in mobile Health (mHealth). Instead of developing a new POC device for every new IVD target, we and others are taking advantage of decades of research, development, engineering and continuous improvement of the blood glucose meter (BGM), including those already integrated with smartphones, and transforming the BGM into a general healthcare meter for POC IVDs of a wide range of biomarkers, therapeutic drugs and other analytical targets. In this review, we summarize methods to transduce and amplify selective binding of targets by antibodies, DNA/RNA aptamers, DNAzyme/ribozymes and protein enzymes into signals such as glucose or NADH that can be measured by commercially available BGM, making it possible to adapt many clinical assays performed in central labs, such as immunoassays, aptamer/DNAzyme assays, molecular diagnostic assays, and enzymatic activity assays onto BGM platform for quantification of non-glucose targets for a wide variety of IVDs in mHealth.

show abstract

“…In these selections, the targets were the crude extracellular mixture, although the exact target molecule has yet to be identified in most cases. In one case, the RFD-CD1 shows very high specificity for a pathogenic strain of Clostridium difficile, and the target was identified to be a unique transcription factor ( Figure 8C) (Shen et al, 2016). The fluorophore/quencher not only provides signal, but also likely directly participates in the molecular recognition/ catalysis since the activity is often lost after removing them.…”

Section: Sensing Of Non-metal Targetsmentioning

confidence: 99%

Catalytic Nucleic Acids: Biochemistry, Chemical Biology, Biosensors, and Nanotechnology

Liu

2020

iScience

126

View full text Add to dashboard Cite

Since the initial discovery of ribozymes in the early 1980s, catalytic nucleic acids have been used in different areas. Compared with protein enzymes, catalytic nucleic acids are programmable in structure, easy to modify, and more stable especially for DNA. We take a historic view to summarize a few main interdisciplinary areas of research on nucleic acid enzymes that may have broader impacts. Early efforts on ribozymes in the 1980s have broken the notion that all enzymes are proteins, supplying new evidence for the RNA world hypothesis. In 1994, the first catalytic DNA (DNAzyme) was reported. Since 2000, the biosensor applications of DNAzymes have emerged and DNAzymes are particularly useful for detecting metal ions, a challenging task for enzymes and antibodies. Combined with nanotechnology, DNAzymes are key building elements for switches allowing dynamic control of materials assembly. The search for new DNAzymes and ribozymes is facilitated by developments in DNA sequencing and computational algorithms, further broadening our fundamental understanding of their biochemistry.

show abstract

A Catalytic DNA Activated by a Specific Strain of Bacterial Pathogen

Cited by 38 publications

References 29 publications

Theranostic DNAzymes

Theranostic DNAzymes

Transforming the blood glucose meter into a general healthcare meter for in vitro diagnostics in mobile health

Catalytic Nucleic Acids: Biochemistry, Chemical Biology, Biosensors, and Nanotechnology

Contact Info

Product

Resources

About